Zacks: Brokerages Expect Cardiff Oncology, Inc. (NASDAQ:CRDF) Will Announce Quarterly Sales of $80,000.00

Brokerages expect Cardiff Oncology, Inc. (NASDAQ:CRDFGet Rating) to report sales of $80,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cardiff Oncology’s earnings, with estimates ranging from $50,000.00 to $100,000.00. Cardiff Oncology posted sales of $70,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Cardiff Oncology will report full year sales of $300,000.00 for the current year, with estimates ranging from $220,000.00 to $370,000.00. For the next year, analysts expect that the business will report sales of $200,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Cardiff Oncology.

Cardiff Oncology (NASDAQ:CRDFGet Rating) last released its quarterly earnings data on Friday, May 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Cardiff Oncology had a negative return on equity of 25.12% and a negative net margin of 9,447.37%.

A number of equities research analysts recently issued reports on CRDF shares. HC Wainwright decreased their price objective on shares of Cardiff Oncology from $25.00 to $22.00 in a report on Monday, May 9th. Maxim Group decreased their price target on Cardiff Oncology from $25.00 to $14.00 in a research note on Monday, January 24th. Zacks Investment Research downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 11th. Finally, Robert W. Baird decreased their target price on Cardiff Oncology from $13.00 to $9.00 in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to, the stock has an average rating of “Buy” and an average price target of $13.00.

Several large investors have recently modified their holdings of CRDF. Point72 Asset Management L.P. bought a new position in shares of Cardiff Oncology in the fourth quarter worth about $3,015,000. Renaissance Technologies LLC bought a new position in Cardiff Oncology in the 1st quarter worth approximately $1,219,000. Morgan Stanley increased its position in Cardiff Oncology by 1,741.2% in the 2nd quarter. Morgan Stanley now owns 467,461 shares of the company’s stock worth $3,109,000 after buying an additional 442,072 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Cardiff Oncology by 12.1% during the third quarter. Janus Henderson Group PLC now owns 3,533,381 shares of the company’s stock worth $23,541,000 after buying an additional 382,214 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Cardiff Oncology in the first quarter valued at approximately $805,000. 56.43% of the stock is currently owned by institutional investors.

Shares of CRDF opened at $1.32 on Tuesday. The company’s fifty day moving average is $1.97 and its 200-day moving average is $3.84. Cardiff Oncology has a 12 month low of $1.13 and a 12 month high of $8.92.

About Cardiff Oncology (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Featured Stories

Get a free copy of the Zacks research report on Cardiff Oncology (CRDF)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with's FREE daily email newsletter.